Clinical Trial Update: Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of TQB2825 injection versus immunotherapy in recurrent or refractory follicular lymphoma; the study st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• TQB2825

Snippet

Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Conditions: Follicular Lymphoma | Phase 3 | Status: NOT_YET_RECRUITING